BRD4 and neoplasm: In contrast, in the current study, we observed remarkable anti‐tumor efficacy of BRD4‐degrading ARV@PDSA Nano‐PROTACs, even when lowering the dose range to 3 and 10 mg ARV‐771/kg, within the tolerated range of commonly studied chemotherapeutics.[41] Indeed, biosafety analysis in the current study showed no significant variations in mouse body weight, and no obvious difference in H&E staining of main organs between groups, further confirming the biocompatibility of the ARV@PDSA Nano‐PROTACs for tumor therapy.